Ciclopirox gel in the treatment of patients with interdigital tinea pedis

Aly, Raza; Fisher, George A.; Katz, H. Irving; Levine, Norman; Lookingbill, Donald P.; Lowe, Nicholas J.; Menter, Alan; Morman, Manuel R.; Pariser, David M.; Roth, Harry L.; Savin, Ronald C.; Shavin, Joel S.; Stewart, Daniel; Taylor, J. Richard; Tucker, Stephen B.; Wortzman, Mitchell

doi:10.1046/j.1365-4362.42.s1.6.x

Cited by 17 publications

(27 citation statements)

References 6 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ciclopiroxolamine (1% and 0·77%) used for 4 weeks was evaluated in two placebo‐controlled trials ( n = 144 30 and n = 317 14 ). A statistically significant relative reduction in treatment failure was observed (RR 0·27, 95% CI 0·11–0·66).…”

Section: Resultsmentioning

confidence: 99%

Are placebo-controlled trials of creams for athlete’s foot still justified?

Crawford¹,

Harris²,

Williams

2008

British Journal of Dermatology

View full text Add to dashboard Cite

The superiority of allylamines and azoles over vehicle in vehicle-controlled trials has been well established, and data demonstrating this fact have been available since the completion of early RCTs. These preparations are effective and safe, and investigators of RCTs evaluating topical treatments for athlete's foot need to choose potential comparators as control interventions in the light of this knowledge and to consider the ethics of withholding effective treatment from patients who seek treatment for this common foot infection.

show abstract

Section: Resultsmentioning

confidence: 99%

Are placebo-controlled trials of creams for athlete’s foot still justified?

Crawford¹,

Harris²,

Williams

2008

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…The unique mechanism of action of ciclopirox, combined with its antibacterial and anti‐inflammatory properties, make it an ideal candidate for the treatment of superficial dermatophyte and yeast infections. This is evidenced by its success in the treatment of interdigital tinea pedis, which often presents as dermatophyte fungus with superimposed bacterial infection and inflammation 1,2 . Seborrheic dermatitis also may involve a combination of fungal infection and inflammatory action, 21 which has been successfully controlled using ciclopirox 14,15 .…”

Section: Discussionmentioning

confidence: 99%

“…Finally, the potential for resistance of organisms to ciclopirox may be lower than for other antifungals 7 . Thus ciclopirox has been used in multiple clinical trials for a wide variety of indications, and years of clinical usage have demonstrated the safety and efficacy of ciclopirox in the treatment of superficial mycoses 1,2,6,11,17,20,22–24 …”

Section: Discussionmentioning

confidence: 99%

“…In the USA, ciclopirox is available in five formulations to treat a variety of superficial mycoses including tinea pedis, tinea corporis/cruris, pityriasis (tinea) versicolor, and seborrheic dermatitis (Table 1). Ciclopirox 0.77% gel has been reported as a successful treatment for tinea pedis 1,2 . Ciclopirox 8% nail lacquer is indicated in the USA for the treatment of onychomycosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ciclopirox: a broad‐spectrum antifungal with antibacterial and anti‐inflammatory properties

Gupta

Plott²

2004

Int J Dermatology

View full text Add to dashboard Cite

“…Posology of the drugs was based on the previous studies and recommended frequency of use (3,4). The diagnosis of tinea pedis was based on the clinical findings and positive potassium hydroxide (KOH) examination.…”

Section: Methodsmentioning

confidence: 99%

Comparison of Efficacy and Safety of Topical 1% Butenafine and Topical 1% Ciclopirox Olamine in the Treatment of Tinea Pedis and Evaluation of the Effects on the Quality of Life of These Treatmens: A Randomized Single-Blind Trial

Polat¹,

Belli²,

Alataş³

et al. 2017

tdd

View full text Add to dashboard Cite

ÖzAmaç: Tinea pedisli hastalarda topikal %1 butenafin ve topikal %1 siklopiroks olaminin etkinlik ve güvenilirliğinin karşılaştırılması ve bu tedavilerin yaşam kalitesi üzerine etkilerinin değerlendirilmesi amaçlandı. Yöntemler: Mayıs 2014 ile Mayıs 2015 tarihleri arasında, tinea pedisli 80 hasta üzerinde randomize kontrollü bir araştırma yapıldı. Bu 80 hastanın 40'ı topikal %1 butenafin krem, diğer 40'ı topikal %1 siklopiroks olamin krem ile bir ay süre ile tedavi edildi. Klinik özellikler, Dermatoloji Yaşam Kalite İndeksi (DLQI) skorları, Doktorun Global Değerlendirmesi (PhGA) ve Hastanın Global Değerlendirmesi kaydedildi. Bulgular: Butenafin tedavisi alan 40 hasta (21 erkek, 19 kadın) ve siklopiroks olamin tedavisi alan 40 hasta (15 erkek, 25 kadın) çalışmaya alındı. Her iki tedavi de klinik bulgu ve semptomları önemli derecede düzeltirken, gruplar arasında anlamlı farklılık saptanmadı (p>0,05). DLQI skorları her iki gruptaki tedavilerden sonra anlamlı olarak azaldı. Rekürrens sadece siklopiroks olamin grubundaki iki hastada gözlendi.Objective: The aim of the study is to compare efficacy and safety of topical 1% butenafine and topical 1% ciclopirox olamine in tinea pedis and to evaluate effects of these treatments on quality of life. Methods: We conducted a randomized controlled trial on 80 patients with tinea pedis between May 2014 and May 2015. Of 80 patients, 40 were treated with 1% butenafine cream and 40 were treated with 1% ciclopirox olamine cream for one month. Clinical characteristics, Dermatology Life Quality Index (DLQI) scores, Physician's Global Assessment (PhGA), and Patient's Global Assessment were recorded. Results: Forty patients (21 male, 19 female) on butenafine therapy and 40 patients (15 male, 25 female) on ciclopirox olamine therapy were enrolled in the study. Both treatments significantly improved the clinical signs and symptoms, but no significant difference was found between the groups (p>0.05). The DLQI scores decreased significantly after the treatments in both groups. The recurrence was observed only in two patients from ciclopirox olamine group. Conclusion: Topical butenafine and ciclopirox olamine had similar high efficacy and safety in the treatment of tinea pedis. In addition, both two drugs had positive improvement on quality of life of the patients.

show abstract

Ciclopirox gel in the treatment of patients with interdigital tinea pedis

Abstract: Ciclopirox gel 0.77% applied twice daily for 4 weeks is an effective treatment of moderate interdigital tinea pedis due to T. rubrum, T. mentagrophytes and E. floccosum and is associated with a low incidence of minor adverse effects.

Cited by 17 publications

References 6 publications

Are placebo-controlled trials of creams for athlete’s foot still justified?

Are placebo-controlled trials of creams for athlete’s foot still justified?

Ciclopirox: a broad‐spectrum antifungal with antibacterial and anti‐inflammatory properties

Comparison of Efficacy and Safety of Topical 1% Butenafine and Topical 1% Ciclopirox Olamine in the Treatment of Tinea Pedis and Evaluation of the Effects on the Quality of Life of These Treatmens: A Randomized Single-Blind Trial

Contact Info

Product

Resources

About